PFE - Pfizer/Mylan agree to FTC conditions for go-ahead on combined drug firm

The U.S. Federal Trade Commission ((FTC)) announces that Pfizer ([[PFE]] -0.7%) and Mylan N.V. ([[MYL]] +1.1%) have agreed to agency conditions for approving the proposed combination of Pfizer's Upjohn unit and Mylan which will do business as Viatris.Citing harm to competition in 10 generic drug markets, seven in the U.S. by reducing the number of suppliers and three where the merger would delay or eliminate a likely entrant thereby reducing the likelihood of price decreases, the agency is requiring product divestment.The seven U.S. product markets are: (1) amlodipine besylate/atorvastatin calcium tablets, which combine a calcium channel blocker to treat hypertension with a lipid-lowering agent to treat high cholesterol; (2) eplerenone tablets, a diuretic prescribed in combination with other medications when treating hypertension or congestive heart failure after a heart attack; (3) phenytoin chewable tablets, which are used to prevent epileptic seizures; (4) prazosin HCl capsules, an alpha-adrenergic blocker that treats

For further details see:

Pfizer/Mylan agree to FTC conditions for go-ahead on combined drug firm